Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561685 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 340
- Enrollment target
- 20
- Study locations
NCT06561685 is a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 340 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06561685, a Phase 1 study of Non-Small Cell Lung Cancer and Advanced Solid Tumor, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 340 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG LY4050784
Study Locations (20)
Tennessee
- Sarah Cannon Research Institute - Nashville
- SCRI Oncology Partners - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Other
- Institut Bergonie - Bordeaux
- Institut Curie - Paris
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP - Villejuif
Colorado
- University of Colorado Health Hospital - Aurora
- Sarah Cannon Research Institute at HealthOne - Denver
Florida
- Florida Cancer Specialists ORLANDO/DDU - Lake Mary
- University of Miami - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- UCLA - Santa Monica
Illinois
- University of Chicago - New Lenox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06561685
The ClinicalTrials.gov registry entry for NCT06561685 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (48% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06561685 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Tennessee, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT06561685 about?
NCT06561685 is a clinical study titled "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors". The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMAR...
What is the current status of trial NCT06561685?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 340 participants. The study started on 2024-09-19. Estimated completion is 2027-10.
What conditions does trial NCT06561685 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor, SMARCA4-Deficient Tumor.
What interventions are being tested in trial NCT06561685?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), LY4050784 (DRUG).
Who is sponsoring clinical trial NCT06561685?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561685 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.